Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.
The inclusion of protease inhibitors (PIs) in highly active antiretroviral therapy has significantly improved clinical outcomes in HIV-1-infected patients. To date, PIs are considered to be the most important therapeutic agents for the treatment of HIV infections. Despite high anti-HIV-1 potency, poor oral bioavailability of PIs has been a major concern. For achieving therapeutic concentrations, large doses of PIs are administered, which results in unacceptable systemic toxicities. Such severe and long-term toxicities necessitate the development of safer and potentially promising PIs. Recently, considerable attention has been paid to the development of newer compounds capable of inhibiting wild-type and resistant HIV-1 protease. Some of these PIs have displayed potent HIV-1 protease inhibitory activity. In this review, we have made an attempt to provide an overview on clinically approved and newly developing PIs, and related recent patents in the development of novel PIs.
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.
Mitesh
M
Patel
Nanda K
NK
Mandava
Ramya Krishna
RK
Vadlapatla
Ashim K
AK
Mitra
D000818:Animals; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010330:Patents as Topic; D011480:Protease Inhibitors / Q000627:therapeutic use*
D011480:Protease Inhibitors